Why a new definition matters
For years “recurrent implantation failure” has meant different things at different clinics. It might mean two failed transfers or five, tested embryos or untested ones. That vagueness matters because the label often unlocks a list of extra tests and treatments.
The ASRM committee opinion on recurrent implantation failure (Fertility and Sterility, 2026) starts by acknowledging that there is no uniform definition. It proposes one based on success probability instead. RIF is the failure to implant after transferring the estimated number of good-quality blastocysts that would normally give a 95% cumulative chance of a positive pregnancy test. Based on current literature, it suggests that is roughly 3 to 6 failed transfers of euploid (chromosomally tested) embryos, or an age-dependent number of untested embryos.
Two details are worth knowing. The opinion uses a positive pregnancy blood test (hCG) as the marker of implantation. It also keeps RIF separate from recurrent pregnancy loss, which requires two pregnancy losses. If you have had positive tests followed by losses, that is a different evaluation.
What the evaluation should include
The core recommendation is to go back through your medical and reproductive history, imaging and the details of each IVF cycle to look for factors that can be corrected. The opinion then addresses specific areas:
- The uterine cavity. Repeating an assessment of the cavity, and of the tubes, with sonohysterography, hysteroscopy, HSG or 3D ultrasound is described as reasonable. Hysteroscopy can also treat what it finds. The evidence for removing polyps and submucosal fibroids is limited but supports offering it. Evidence is insufficient for treating fibroids that do not distort the cavity.
- Parental chromosomes. Karyotyping both partners may be considered to look for a structural rearrangement. If one is found, genetic counselling is recommended and PGT-SR may be offered. The opinion notes such findings were present in only about 2–3% of recent RIF groups studied.
- Embryo testing. PGT-A may be offered for untested embryos through shared decision-making. The opinion states plainly that there is no evidence PGT-A increases the chance of live birth in RIF.
- The transfer itself. Following ASRM’s embryo transfer guidance is recommended, and cervical dilation beforehand may help people whose previous transfers were difficult.
- Endometriosis or adenomyosis. A course of GnRH agonist plus an aromatase inhibitor before transfer “may be considered” where these are known or suspected, though this rests on a single retrospective study. Our guide to endometriosis and IVF covers that diagnosis.
- Chronic endometritis. Testing and antibiotic treatment may be considered on observational evidence, but because diagnostic criteria are not standardised this is not a routine recommendation.
- Lifestyle. Stopping smoking, reaching a healthy weight and avoiding alcohol and recreational drugs are advised for general health and pregnancy. The authors note these changes have not been shown to improve RIF outcomes specifically.
Tests and treatments the opinion does not support
This is the section most likely to change what you are offered. The table summarises the opinion’s conclusions.
| Test or treatment | ASRM 2026 conclusion |
|---|---|
| Endometrial receptivity analysis (ERA) | Insufficient evidence for routine use. Two randomised trials did not show higher live birth rates, and one analysis found poor predictive accuracy. |
| BCL-6 testing | Routine testing not recommended |
| Endometrial scratch | Not effective and not recommended, given a large 2019 trial showing no benefit |
| Thrombophilia or antiphospholipid testing, routine heparin | Insufficient data to support routine use |
| Intralipid (fat emulsion) infusions | Insufficient evidence |
| IVIG | Not recommended |
| G-CSF | Insufficient evidence |
| Etanercept | Insufficient evidence; randomised trials needed |
| Intrauterine hCG infusion | Conflicting results; randomised trials needed |
| Intrauterine PRP | Insufficient evidence; most studies lack controls |
| Sperm DNA fragmentation testing | Insufficient evidence for RIF |
| A specific progesterone regimen for RIF | Insufficient data to recommend one |
“Insufficient evidence” does not mean proven harmful. It means the treatment has not been shown to help, so paying for it, and sometimes delaying another transfer for it, is a bet rather than standard care. If a clinic recommends one of these, ask why it thinks your case is the exception and whether it would offer the treatment within a research study.
If nothing correctable is found
This may be the most reassuring part of the opinion. If a careful review turns up no correctable cause, the committee says extensive further testing is unnecessary and further transfers are reasonable, because many patients eventually conceive. It also recommends offering social support after failed transfers, and says a gestational carrier can be considered after several failures.
That framing is a useful antidote to the feeling that something must be done differently every time. Sometimes the evidence-based next step is another well-run transfer of a good embryo.
What the opinion does not settle
The committee is open about the limits of the evidence. Much of the research on RIF used different definitions, small numbers of patients or no control group, which is one reason so many treatments end up as “insufficient evidence”. The opinion concludes that high-quality prospective studies using one agreed definition are needed. For you, that means two things. A clinic that is honest about uncertainty is not being unhelpful. And if you are offered an experimental treatment, asking whether it is being given within a properly designed study is a reasonable question, not an awkward one.
It also means emotional support is part of the plan, not an extra. Repeated failed transfers are draining, and the opinion specifically recommends offering social support. If your clinic does not provide counselling, ask your doctor at home for a referral before your next attempt.
Taking a history of failed transfers to a Medellín clinic
If you are considering a Medellín clinic after failures elsewhere, the opinion gives you a frame for judging the consultation.
Prepare a transfer-by-transfer summary
List each transfer with its date, the embryo’s stage and grade, whether it was tested, the type of cycle, the lining measurement if known, any difficulty during the procedure and the pregnancy test result. That table is what a doctor needs to judge whether you meet the probability-based definition at all. Our guide to getting a second opinion after a failed cycle covers the wider record set.
Judge the proposed plan
A plan in line with the 2026 opinion will usually start by reviewing what has already been done. It may suggest repeating a cavity assessment, considering karyotyping, and looking at transfer technique and any endometriosis. A plan that opens with a bundle of immune treatments, receptivity testing and endometrial scratching, without discussing the evidence, deserves careful questions. Our guide to IVF add-ons in a Medellín quote explains how to ask for that evidence.
Think about embryo testing carefully
If your earlier embryos were untested, a clinic may suggest PGT-A next time. ASRM’s 2024 PGT-A opinion and the 2026 RIF opinion both stop short of saying it improves live birth rates. It can help you understand what happened, and it will reduce the number of embryos available. Decide with your doctor whether that information is worth the trade-off.
Questions worth taking to the consultation
- Do I meet the 2026 ASRM definition, given my age and the embryos transferred?
- What correctable factors have you found in my history, imaging or cycle records?
- Should my uterine cavity be reassessed, and by which method?
- Is karyotyping for my partner and me worth considering?
- For any add-on you recommend, what does the 2026 opinion say about it, and why is my case different?
- If nothing correctable is found, what would my next transfer look like?
Already have a fertility treatment quote?
Compare the scope before comparing the sticker price. If you are gathering written estimates, keep the medication, laboratory, freezing, transfer and follow-up lines separate.
Compare a medical quoteExplore Colombia medical careConsidering fertility care in Medellín?
Use the private planning request to describe what you are comparing, your approximate timing and travel readiness. Do not upload medical records; a provider can move clinical information into its secure intake.
Request a fertility introductionCompare written quotesFrequently asked questions
How many failed transfers count as recurrent implantation failure?
There is no single agreed number. ASRM’s 2026 opinion ties the definition to the number of good-quality blastocysts that would normally give a 95% cumulative chance of a positive pregnancy test. In practice it suggests that is roughly 3 to 6 failed transfers of chromosomally tested embryos, or an age-dependent number of untested ones.
Should I have an endometrial receptivity test after failed transfers?
ASRM’s 2026 opinion finds the evidence insufficient to recommend it routinely. It notes that two randomised trials did not show higher live birth rates and that one analysis found the test predicted outcomes poorly. Ask any clinic recommending it what it expects the result to change.
Do immune treatments like intralipids or IVIG help after failed IVF transfers?
The 2026 opinion says the evidence is insufficient for intralipids and G-CSF and does not recommend IVIG. It reaches similar conclusions about several other immune or intrauterine treatments. These should not be presented as standard care for repeated implantation failure.
Is it reasonable to keep transferring if no cause is found?
Yes, according to ASRM. If a careful review finds nothing correctable, the 2026 opinion says extensive testing is unnecessary and further transfers are reasonable, because many patients eventually conceive.
Would PGT-A help after several failed transfers?
The opinion says PGT-A may be offered for untested embryos through shared decision-making, but that there is no evidence it increases the chance of live birth in this group. Discuss what you would gain and lose before adding it.
Is a gestational carrier ever recommended after failed transfers?
ASRM’s 2026 opinion says a gestational carrier can be considered after several failed transfers. It is a significant personal, legal and financial decision, and it usually comes after the other evaluation steps.
Research sources
Primary and reference sources used for this article:
Medical disclaimer: MedellinIVF.co is an independent educational and lead-navigation site, not a fertility clinic. Nothing on this page is diagnosis, treatment advice or a guarantee of outcome. Prices and policies change. Verify current information directly with the treating clinic and appropriate Colombian registries.